Theravance (NASDAQ:TBPH) said that it and partner Mylan have granted Teva (NYSE:TEVA) a royalty-free, non-exclusive license to market a generic version of their drug Yupelri in the US on or after April 23, 2039, as part of a settlement of their patent litigation
Theravance and Mylan had sued Teva over its attempts to market a generic version of Yupelri, also known as revefenacin, before the drug’s Orange Book-listed patents had expired. The deal is subject to approval by the US Department of Justice and Federal Trade Commission, according to an SEC filing on Monday.
Yupelri is owned by Theravance and licensed to Mylan, which is now part of Viatris (NASDAQ:VTRS). The drug is used to treat COPD.